Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Authors

Institutions

Publication Details

Journal
EBioMedicine
Published
2024-10-11
DOI
https://doi.org/10.1016/j.ebiom.2024.105374
Citations
8
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
2.26

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Álvaro Taus, Muriel Richard, Mahmut Gümüş, Susana Roselló‐Keränen et al.
8 citations
EBioMedicine
Cancer Immunotherapy and Biomarkers
2.26
article

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Álvaro Taus, Muriel Richard, Mahmut Gümüş, Susana Roselló‐Keränen, Çağatay Arslan, Nassim Sleiman, Colin R. Lindsay, Eva María Guerra Alia, A. Yu. Smolin, Daniel Marbach, Ruth Perets, Vladimir Moiseyenko, Diégo Tosi, Nino Keshelava, Iwona Ługowska, Sylvie Rottey, Stefan Evers, Sema Sezgin Göksu, David Dejardin, Rafał Dziadziuszko, İrfan Çiçin, Hans Prenen, Antoîne Italiano, Christophe Boetsch, Ana Oaknin, Sanjeev Deva, Anton Kraxner, Loïc Verlingue, Jehad Charo, Volker Teichgräber, Caroline Ardeshir, Christin Habigt
article en
8 citations

Abstract

No abstract available for this paper.
EBioMedicineVol. 109
Roche (Switzerland) (CH), Trakya University (TR), Izmir University (TR), Akdeniz University (TR), Instituto Cajal (ES), Ghent University Hospital (BE), Rambam Health Care Campus (IL), Auckland City Hospital (NZ), Institut Gustave Roussy (FR), Antwerp University Hospital (BE), Roche (United Kingdom) (GB), Burdenko Neurosurgery Institute (RU), Vall d'Hebron Hospital Universitari (ES), Hospital Del Mar (ES), The Christie NHS Foundation Trust (GB), Institut Bergonié (FR), Institut de Recherche en Cancérologie de Montpellier (FR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), INCLIVA Health Research Institute (ES), Republican Scientific and Practical Center of Neurology and Neurosurgery (BY), Vall d'Hebron Institute of Oncology (ES), Istanbul Medeniyet University (TR), Gdańsk Medical University (PL)
F. Hoffmann-La Roche
Good health and well-being
Openalex Percentile: Top 10%
Cancer Immunotherapy and Biomarkers
2.26
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.